title: Cryptococcosis in Patients With Cirrhosis of the Liver and Posttransplant Outcomes.
abstract: BACKGROUND
  The outcomes and optimal management of cirrhotic patients who develop cryptococcosis before transplantation are not fully known.
  
  
  METHODS
  We conducted a multicenter study involving consecutive patients with cirrhosis and cryptococcosis between January 2000 and March 2014. Data collected were generated as standard of care.
  
  
  RESULTS
  In all, 112 patients were followed until death or up to 9 years. Disseminated disease and fungemia were present in 76.8% (86/112) and 90-day mortality was 57.1% (64/112). Of the 39 patients listed for transplant, 20.5% (8) underwent liver transplantation, including 2 with active but unrecognized disease before transplantation. Median duration of pretransplant antifungal therapy and posttransplant therapy was 43 days (interquartile range, 8-130 days) and 272 days (interquartile range, 180-630 days), respectively. Transplantation was associated with lower mortality (P = 0.002). None of the transplant recipients developed disease progression during the median follow-up of 3.5 years with a survival rate of 87.5%.
  
  
  CONCLUSIONS
  Cryptococcosis in patients with cirrhosis has grave prognosis. Our findings suggest that transplantation after recent cryptococcal disease may not be a categorical exclusion and may be cautiously undertaken in liver transplant candidates who are otherwise deemed clinically stable.
authors: 1 Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA. 2 University of Virginia, Charlottesville, VA. 3 University of Iowa, Iowa City, IA. 4 University of Michigan, Ann Arbor, MI. 5 Icahn School of Medicine at Mount Sinai, New York, NY. 6 University of Washington, Seattle, WA. 7 Vanderbilt University, Nashville, TN. 8 Baylor Health System, Dallas, TX. 9 Cleveland Clinic, Cleveland, OH. 10 Yale School of Medicine, New Haven, CT. 11 University of Texas Southwestern Medical Center, Dallas, TX. 12 Johns Hopkins University, Baltimore, MD. 13 University of Kansas, Kansas City, KS. 14 Mayo Clinic, Rochester, MN. 15 University of South Florida, Tampa, FL. 16 University of Pennsylvania, Philadelphia, PA. 17 University of Miami, Miller School of Medicine, Miami, FL. 18 Department of Surgery, St. Luke's Hospital, Kansas City, MO. 19 Henry Ford Hospital, Detroit, MI. 20 Virginia Commonwealth University, Richmond, VA. 21 Department of Internal Medicine, National Taiwan University Hospital and National, Taipei, Taiwan.
authors: Nina
authors: N
authors: Singh
authors: Costi D
authors: CD
authors: Sifri
authors: Fernanda P
authors: FP
authors: Silveira
authors: Rachel
authors: R
authors: Miller
authors: Kevin S
authors: KS
authors: Gregg
authors: Shirish
authors: S
authors: Huprikar
authors: Erika D
authors: ED
authors: Lease
authors: Andrea
authors: A
authors: Zimmer
authors: J Stephen
authors: JS
authors: Dummer
authors: Cedric W
authors: CW
authors: Spak
authors: Christine
authors: C
authors: Koval
authors: David B
authors: DB
authors: Banach
authors: Miloni
authors: M
authors: Shroff
authors: Jade
authors: J
authors: Le
authors: Darin
authors: D
authors: Ostrander
authors: Robin
authors: R
authors: Avery
authors: Albert
authors: A
authors: Eid
authors: Raymund R
authors: RR
authors: Razonable
authors: Jose
authors: J
authors: Montero
authors: Emily
authors: E
authors: Blumberg
authors: Ahlaam
authors: A
authors: Alynbiawi
authors: Michele I
authors: MI
authors: Morris
authors: Henry B
authors: HB
authors: Randall
authors: George
authors: G
authors: Alangaden
authors: Jeffrey
authors: J
authors: Tessier
authors: Marilyn M
authors: MM
authors: Wagener
authors: Hsin Yun
authors: HY
authors: Sun
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D003453:Cryptococcosis / Q000150:complications*; D018450:Disease Progression; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000150:complications* / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D066027:Transplant Recipients; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole